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Protein name recognition aims to detect each and every protein names appearing in a PubMed abstract. The task is not simple, as
the graphic word boundary (space separator) assumed in conventional preprocessing does not necessarily coincide with the protein
name boundary. Such boundary disagreement caused by tokenization ambiguity has usually been ignored in conventional prepro-
cessing of general English. In this paper, we argue that boundary disagreement poses serious limitations in biomedical English text
processing, not to mention protein name recognition. Our key idea for dealing with the boundary disagreement is to apply tech-
niques used in Japanese morphological analysis where there are no word boundaries. Having evaluated the proposed method with
GENIA corpus 3.02, we obtain F-measure of 69.01 on a strict criterion and 79.32 on a relaxed criterion. The result is comparable to
other published work in protein name recognition, without resorting to manually prepared ad hoc feature engineering. Further,
compared to the conventional preprocessing, the use of morphological analysis as preprocessing improves the performance of pro-
tein name recognition and reduces the execution time.
 2004 Elsevier Inc. All rights reserved.
Keywords: Protein name recognition; Named entity recognition; Morphological analysis; Tokenization and part-of-speech ambiguity; Changing
nomenclature in biomedicine; SVMs (kernel method) and feature engineering1. Introduction
Text mining has been one of many alternative ap-
proaches to extract and aggregate ‘‘relevant’’ informa-
tion for biomedical research. In the ﬁeld of molecular
biology, genomes of various model species including the
human genome have been released. Given such advances,
the focus of attention has moved to understanding func-
tions of genes and proteins. In particular, retrieval of1532-0464/$ - see front matter  2004 Elsevier Inc. All rights reserved.
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Konagaya), matsu@is.naist.jp (Y. Matsumoto).published biomolecular interactions, most notably pro-
tein–protein interactions, from PubMed abstract (e.g.,
[8]) becomes valuable, not only to comprehend the cur-
rent status but also to plan new biological experiments.
In this paper, we describe protein name recognition,
which is a fundamental precursor to biomedical text min-
ing. The task of protein name recognition involves detect-
ing each and every protein name in an abstract. This will
facilitate advanced biomedical text processing, such as
indexing of protein names within articles, and retrieving
evidence passage of biomolecular function descriptions.
Accurate protein name recognition may lessen the bur-
den involved in biomolecular database curation.
The main topic of this paper is augmentation of
preprocessing so as to attain accurate protein name
recognition. We argue that tokenization ambiguity
472 K. Yamamoto et al. / Journal of Biomedishould not be overlooked, by illustrating problems stem-
ming from tokenization in biomedical text. The key idea
to deal with tokenization ambiguity is to view biomedi-
cal English text as if it were the text of a non-segmented
language such as Chinese or Japanese. Our proposal is
to apply Japanese morphological analysis techniques
to biomedical English text processing. This enables us
to resolve tokenization ambiguity as well as part-of-
speech tagging ambiguity. Performance of protein name
recognition has been improved when using our morpho-
logical analyzer instead of a conventional tokenizer and
part-of-speech tagger, which do not take tokenization
ambiguity into account.
The rest of paper is organized as follows. Section 2
describes issues in protein name recognition, and Sec-
tion 3 provides a short review of related work. Together,
our motivation to augment preprocessing, i.e., replacing
conventional preprocessing by morphological analysis,
will be clear. Section 4 gives an overview of a supervised
learning approach for protein name recognition, Section
5 presents the core of our proposal, morphological anal-
ysis for biomedical text, and Section 6 reports our exper-
imental evaluation of the proposed method. Finally,
concluding remarks are given in Section 7.2. Issues in protein name recognition
Protein name recognition is a special case of biomed-
ical named entity recognition (NER), and we identify
three issues in biomedical NER:
1. Tokenization ambiguity. The graphic word boundary
assumed in conventional preprocessing does not nec-
essarily coincide with the protein name boundary.
2. Changing nomenclature. Vocabularies have many
variants (a.k.a. synonyms) and are constantly chang-
ing over time. However, (a) underlying context are
most likely time-invariant though spelling may be
slightly altered, and (b) up-to-date expert knowledge
resources are publicly available via sequence dat-
abases and ontologies.
3. Feature engineering. Protein names and other bio-
medical NEs share similar orthographic features.
Feature engineering to derive eﬀective feature combi-
nation (e.g., orthographic feature plus contextual fea-
ture) will be necessary to deliver a good performance.Fig. 1. Boundaries of biomedic2.1. Tokenization ambiguity
In biomedical NER, it is diﬃcult to determine an en-
tity boundary due to tokenization ambiguity. An illus-
trative example is shown in Fig. 1.
As we see from Fig. 1, biomedical NEs are not neces-
sarily segmented by space characters. If we wish to
retrieve information about ‘‘B-cell-speciﬁc activator
protein,’’ then the character ‘‘-’’ in the graphic word
‘‘protein-binding’’ acts as boundaries.
In conventional English processing, a graphic word is
taken as a primary unit of text processing. Notion of a
graphic word is described in the textbook [13], and is
coined by Kucˇera and Francis (1967) as ‘‘a string of con-
tiguous alphanumeric characters with space on either
side; may include hyphens and apostrophes, but no
other punctuation marks.’’
Boundaries of graphic words diﬀer from boundaries
of biomedical NEs. Hence, biomedical text processing
should take note of boundary disagreement, and mini-
mize both under-segmentation and over-segmentation.
Under-segmentation is a situation that arises when a
unit could be divided further. In the two strings denot-
ing the same protein complex,
T-cell receptor/CD3 complex
CD3–T-cell receptor complex
graphic words ‘‘receptor/CD3’’ and ‘‘CD3–T-cell’’ are
under-segmented units since they disagree with the
boundaries of proteins ‘‘T-cell receptor’’ and ‘‘CD3.’’
Over-segmentation is a situation that arises when a
unit is aggressively divided so that superﬂuous ambigu-
ity is introduced. Latin origin words such as species
name (e.g., ‘‘Homo sapiens,’’ ‘‘Escherichia coli’’) or aca-
demic compound (e.g., ‘‘in vivo,’’ ‘‘in vitro’’) should not
be over-segmented since these are cases where a space
character does not truly represents a word separator.
Over-segmenting into ‘‘in’’ and ‘‘vivo’’ introduces
unnecessary part-of-speech ambiguity with a common
preposition ‘‘in.’’
2.2. Changing nomenclature
The issue of changing nomenclature has been well
recognized in the community. We address the issue
based on two observations.
cal Informatics 37 (2004) 471–482al named entities (NEs).
1 Authors in [21] only experimented with innermost (shortest)
biomedical NEs appearing in text.
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sic form of context in text processing is part-of-speech.
Previous work (e.g., [5,19]) used a tokenizer and a
part-of-speech tagger tuned to the Penn Treebank Wall
Street Journal corpus [17]. Authors in [19] mentioned
that part-of-speech annotation was not useful for bio-
medical NER. We also experienced that such oﬀ-the-
shelf preprocessors tend to be ineﬀective in protein name
recognition, since characteristics of PubMed abstract
and Wall Street Journal articles are quite diﬀerent.
Training part-of-speech taggers on annotated Pub-
Med abstract does partially remedy the problem.
Authors in [20] prepared a corpus of 7000 manually
tagged abstracts with a new GENE tag, and trained a
part-of-speech tagger to extract gene–protein names
using transformation-based error-driven learning [2].
Thanks to recent eﬀorts in the community, part-of-
speech annotated PubMed corpora have become avail-
able. The subset of the corpus in [20] is released as Task
1A of BioCreAtIve Evaluation [3]. GENIA Corpus
3.02p [16] is also a collection of part-of-speech tagged
PubMed abstracts that are publicly available.
The above annotated PubMed corpora follow a tag-
ging speciﬁcation nearly compliant to the Penn Tree-
bank, which is not intended to cover language
phenomena speciﬁc to biomedical domain. A strict
adherence to the speciﬁcation, especially graphic words
involving symbols (e.g., hyphen(-) or slash (/)), some-
times results in annotation inconsistency. Examples are
found in GENIA corpus 3.02p:
granulocyte–macrophage/JJ colony-stimulating/JJ fac-
tor/NN;
granulocyte/NN macrophage-colony/NN stimulating/
NN factor/NN.
In fact, both of the above annotations are legitimate.
Hyphenated words are normally tagged as adjective (JJ),
but any token sandwiched between nouns (NN) are
tagged as noun (NN). Hyphens are inserted arbitrarily,
making tokenization and part-of-speech tagging highly
ambiguous. We are confronted by ‘‘data sparsity,’’ the
critical problem in statistical NLP. As a consequence,
it becomes diﬃcult to train a reliable part-of-speech
tagger.
The second observation concerns exploitation of
external resources. In the biomedical domain, expert
knowledge resources are publicly available in the form
of sequence databases or ontologies, most of which are
constantly updated. Incorporation of the external re-
sources into preprocessing not only increases robustness
to spelling variants but also reduces the number of un-
known instances.
In a conventional preprocessing of biomedical NER,
tokenization, part-of-speech tagging and matching to
external resources are regarded as independent subtasks
(e.g., [20,19]). Entries in the external resources aremostly compounds (i.e., multiple graphic words), and
ideally, they should inﬂuence tokenization so as to avoid
over-segmentation. The pipelined preprocessing cannot
deal with such dependency.
2.3. Feature engineering
The ﬁnal issue in biomedical NER is in deciding use-
ful characteristics for protein name recognition. Much
eﬀort in adapting NER to the biomedical domain in-
volves exploitation of eﬀective features (e.g., [18]). Nei-
ther eﬀective features nor relative weights of dependent
feature interactions is known prior to training. Thus,
previous work often selects feature combinations heuris-
tically to deliver a good performance. The approach is
not only tedious, but also it may miss some important
feature interactions not obvious to human.3. Related work
Like our approach (that will be described in the next
section), much literature exists that use a supervised
learning approach in biomedical NER (e.g.,
[18,15,19]). Diﬀerences in these methods boil down to
the type of machine learning algorithm and features
being exploited. Our work is distinguished from others
in that we acknowledge tokenization ambiguity in bio-
medical text and propose augmented preprocessing to
address the issue.
Alternatives to the supervised learning approach are
an approximate string matching approach and a rule-
based approach. Although approximate string matching
approaches successfully overcame the problem of spell-
ing variants, they suﬀered from inaccurate boundary
detection of biomedical NEs [9], or applied only to short
biomedical NEs [21].1 The approaches may not be suc-
cessful for a complete biomedical NER, since matching
longer names means a greater proximity of approxima-
tion, where similarity is based only on spelling. In con-
trast, our tokenization uses exact matching of common
substrings against a dictionary of morphological analy-
sis, and chunking can use richer features other than
spelling. Hence, our approach is potentially more robust
for any given length of biomedical NEs.
The pilot study in a rule-based approach was con-
ducted by [5], and there are many followers (e.g., [14]).
The approach has an advantage that it does not require
annotated corpus. However, protein names and other
biomedical NEs share similar orthographic features. It
is prohibitive to heuristically enumerate individual rules
that classify protein names, where rules are often corre-
474 K. Yamamoto et al. / Journal of Biomedical Informatics 37 (2004) 471–482lated. In contrast, a supervised learning approach can be
designed to distinguish protein names from other bio-
medical NEs. Beside this, the rule-based approaches also
used conventional preprocessing which ignored tokeni-
zation ambiguity.j2SV4. A supervised learning approach to protein name
recognition
4.1. Protein name recognition by chunking
Protein name recognition is casted as a sequential
labeling problem (a.k.a. chunking in NLP), and the
model of chunk labels is trained in a supervised way.
The approach has been successful in similar NLP prob-
lems such as base noun phrase bracketing and shallow
parsing. Conference on computational natural language
learning (CoNLL) holds a shared task contest on those
chunking tasks, and chunk labels such as IOB2 are used
in those contests [22].
As shown in Fig. 2, the supervised learning approach
consists of a training phase (vertical arrow) and a testing
phase (horizontal arrow). In training, annotated sen-
tences ﬁrst perform preprocessing, and features are then
extracted. These features are used in a supervised ma-
chine learning algorithm to train a model. In testing,
raw (unannotated) sentences perform the same prepro-
cessing and feature extraction as training, and apply
the trained model to obtain the output sentences which
are now tagged.
Training data is the GENIA corpus 3.02 where bio-
medical NEs are hand tagged by biologists (independent
of the part-of-speech annotated GENIA corpus 3.02p).
In general, chunks are contiguous strings. However, bio-
medical NEs are not strictly chunks, and may have over-
lapping or recursive structures, as illustrated in Fig. 1.
In this paper, we simplify the deﬁnition of protein
names to chunks, as was done in the BioCreAtIve Task
1A Guideline [3]. We deﬁne protein names in GENIA
corpus 3.02 as strings which are enclosed by XML
semantic tags preﬁxed with G#protein and are outer-
most except G#other_names. For example, ‘‘B-cell-
speciﬁc activator protein’’ inFig. 2. Supervised learning approach<protein>B-cell-speciﬁc activator protein</pro-
tein> (BSAP) is a recently identiﬁed member of the
Pax-gene family of transcription factors; in the lym-
phoid system, BSAP is produced only in B-cells.
is a protein name, but ‘‘B-cell-speciﬁc activator protein’’
in
Using this assay, we also showed that Pax-5d was pres-
ent in nuclear extracts of some (but not all) B-lymphoid
lines and interacts with the <dna><protein>
B-cell-speciﬁc activator protein<protein>-binding
site</dna>.
is not, since ‘‘B-cell-speciﬁc activator protein-binding
site’’ is a DNA fragment.
IOB2 chunk labels from the CoNLL shared task are
used to represent protein names. We extend chunk labels
to represent position (Inside, Outside, and Begin) and
class (protein and term) combined. Five chunk labels
B-protein, I-protein, B-term, I-term, and O
are used. B-protein and I-protein encode protein
names, while B-term and I-term encode outermost
biomedical terms (preﬁxed with G#) that are not protein
names. In Fig. 3, B-cell-speciﬁc activator protein and
BSAP are encoded by B-protein and I-protein,
while Pax-gene family is encoded by B-term and I-
term. We use B-term and I-term to reduce an imbal-
ance of a chunk label distribution in the training data.
Otherwise, O labels become too dominant against other
labels, generally resulting a poor performance.4.2. Support vector machines
We use support vector machines (SVMs) to train
models for chunk labels. SVMs are a binary classiﬁer
for a set of training data ðx1; y1Þ; . . . ; ðxL; yLÞxj 2
RN ; yj 2 fþ1;1g, where xj is a feature vector of the
jth training sample, and yj is the class label associated
with the jth training sample. The decision function is
deﬁned by
yðxÞ ¼ sgn
X
yjaj/ðxjÞ  /ðxÞ þ b
 !
; ð1Þto protein name recognition.
Fig. 3. IOB2 chunk labels to represent biomolecular names. Preprocessing determines tokenization (indicated by lines) and part-of-speech (written as
Penn Treebank style). In training, chunk labels where position and class are combined (e.g., B-protein) will be annotated. In testing, the position
part of the estimated chunk label determines boundary and the class part decides if the substring is of protein, term or the other class.
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(N H), aj; b 2 R; aj P 0, and SV is a set of support
examples. The mapping function / should be designed
such that all training examples are linearly separable
in RH space. SVMs take a maximal margin strategy in
that the parameters are chosen so that the minimum dis-
tance between examples and the separating hyperplane
(i.e., margin) is maximized.
SVMs have been successful in practical applications
by virtue of the kernel trick. Since N H, an explicit
calculation of a dot product /(xi) Æ /(x) is heavy. How-
ever, the dot product can be substituted by a kernel
function K(x1,x2) = /(x1) Æ /(x2) which implicitly calcu-
lates the dot product. With the kernel trick, we have the
following decision function:
yðxÞ ¼ sgn
X
j2SV
yjajKðxj; xÞ þ b
 !
: ð2Þ
The kernel we apply is a polynomial kernel which is de-
ﬁned as
Kdðxj;xÞ ¼ 1þ ðxj  xÞ
 d
: ð3Þ
The polynomial kernel expands conjunctive features
implicitly without loss of generality nor an increase in
computational costs. We use a quadratic kernel (d = 2)
which implies that feature combinations of size 1 and
2 are automatically considered. This is particularly
desirable in protein name recognition, since we do not
have to resort to ad hoc feature engineering of eﬀective
feature combinations.
Protein name recognition is a multi-label classiﬁca-
tion. Extending from a binary label classiﬁcation to a
multi-label classiﬁcation is necessary. For this, we use
a pair-wise method that constructs kC2 binary classiﬁers.
Since there are ﬁve chunk labels, k = 5.4.3. Our challenge: augmented preprocessing
The performance of protein name recognition de-
pends on feature extraction, which in turn, relies on pre-
processing (cf. Fig. 2). Out of three issues described in
Section 2, feature engineering can be done without heu-
ristic-driven feature selection by choosing SVMs and the
polynomial kernel as our supervised learning algorithm.
Remaining issues, tokenization ambiguity and changing
nomenclature, relate to preprocessing. Our proposal is
to apply Japanese morphological analysis techniques
to biomedical English text so that both tokenization
and part-of-speech tagging can be tuned for the biomed-
ical domain.5. Morphological analyzer for biomedical text processing
5.1. Markov model
Our morphological analyzer is a classic Markov mod-
el trained on a part-of-speech annotated corpus. It con-
structs a trellis where each node is a substring coupled
with its part-of-speech, and uses the Viterbi algorithm
to select an optimal path in the trellis which corresponds
to a segmentation with the maximum generation
probability.
An example trellis built for a sentence beginning with
‘‘B-cell-speciﬁc activator protein-binding site’’ is illus-
trated in Fig. 4. Each box contains substring (‘‘B-cell’’),
part-of-speech (‘‘NN’’) and word observation cost
(‘‘6301’’) converted from word observation probability.
The part-of-speech tags nearly follow the Penn Tree-
bank tagging guideline with some modiﬁcations de-
scribed in Section 5.2. There are virtual boxes ‘‘BOS’’
and ‘‘EOS’’ for the begin and the end of a sentence
Fig. 4. Example trellis built in morphological analysis.
2
GENIAcorpus3.02.merged.xml.
3
GENIAcorpus3.02.xml.
4
GENIAcorpus3.02.pos.xml.
5 The Penn Treebank tokenizer http://www.cis.upenn.edu/
treebank/tokenization.html is implemented as a collection of
rules (regular expressions).
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tion probability, i.e., the probability of a word given a
tag, while numbers on an edge relates to a tag connec-
tion probability, i.e., the probability of the current tag
given the two previous tags. A formal derivation will
be presented later. It is important to note that the trellis
can represent both tokenization ambiguity (‘‘B-cell’’)
and part-of-speech ambiguity (‘‘binding’’), as shown in
Fig. 4.
Formally, the task of morphological analysis is to
ﬁnd a word sequence W  ¼ w1; . . . ; wn and tag sequence
T  ¼ t1; . . . ; tn that maximize the probability of ÆW*,T*æ
deﬁned as:
hW ; T i ¼ argmax
hW ;T i
P ðT jW Þ ð4Þ
¼ argmax
hW ;T i
P ðW jT ÞP ðT Þ
P ðW Þ ð5Þ
¼ argmax
hW ;T i
P ðW jT ÞP ðT Þ ð6Þ
’ argmax
hW ;T i
Y
i
pðwijtiÞpðtijti2; ti1Þ: ð7Þ
Parameters to estimate from an annotated corpus are
decomposed into tag connection probability
p(ti|ti2,ti1) and word observation probability p(wi|ti).
They are substituted by counting frequencies in the
training corpus:
pðtijti2; ti1Þ ¼ freqðti2; ti1; tiÞfreqðti2; ti1Þ ; ð8Þ
pðwijtiÞ ¼ freqðwi; tiÞfreqðtiÞ : ð9Þ
Had we directly used probabilities, we would suﬀer from
underﬂow in calculation, as probabilities for a long sen-
tence become extremely low. To remedy this, we convert
the probability to the cost which is deﬁned as a log of an
inverse of the probability. As a result, maximizing the
probability product becomes minimizing the cost addi-
tion. Now, Eq. (7) becomes¼ arg min
hW ;T i
Y
i
1
pðwijtiÞ
1
pðtijti2; ti1Þ ð10Þ
¼ arg min
hW ;T i
log
Y
i
1
pðwijtiÞ
1
pðtijti2; ti1Þ ð11Þ
¼ argmin
hW ;T i
X
i
log
1
pðwijtiÞ þ log
1
pðtijti2; ti1Þ
 
: ð12Þ
Numbers in Fig. 4 are actual costs calculated from
probabilities.
In summary, our morphological analyzer gives an
‘‘optimal’’ segmentation with part-of-speech annota-
tion, statistically resolving both tokenization ambiguity
and part-of-speech ambiguity.
5.2. Corpus modiﬁcation for better parameter estimation
For parameter estimation, we use the GENIA 3.02
merged corpus2 of biomedically annotated corpus3 and
part-of-speech annotated corpus4. Note that token
boundaries in the part-of-speech annotated corpus are
automatically determined by the Penn Treebank toke-
nizer,5 while NE boundaries in the biomedically anno-
tated corpus are manually determined by biologists.
Boundary disagreement is removed in the merged cor-
pus by dividing tokens in the part-of-speech annotated
corpus to be consistent with NE boundaries in the biom-
edically annotated corpus. Table 1 summarizes the num-
ber of observed disagreements for each biomedical NE
tag in the merged corpus. All are victims of under-
segmentation.
Under-segmentation instances should be removed
from the corpus as they appear to be harmful to biomed-
Table 1
(a) Boundary disagreement frequency between the merged corpus and
the part-of-speech annotated; (b) frequency of terms in the merged
corpus; (c) disagreement ratio
(a) (b) (c)
Total 6686 83,890 0.08
G#protein 2963 32,303 0.09
G#other_name 1490 17,885 0.08
G#organic 706 6618 0.11
G#cell 524 10,530 0.05
G#(DNA|RNA) 523 10,492 0.05
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sparsity and to increase consistency for graphic words
with symbols. With this in mind, the merged corpus is
modiﬁed as follows:
 Symbols in biomedical text have arbitrary usage and
it is hard to determine their usage from the context.
We introduce lexicalized tags6 for symbols to reduce
under-segmentation and annotation inconsistency.
Symbols ‘‘-,’’ ‘‘/,’’ and ‘‘+’’ are tentatively made as
lexicalized tags.
s granulocyte–macrophage/JJ
ﬁgranulocyte/NN -/- macrophage/NN
 In biomolecular names, Roman and Greek alphabets
are used interchangeably. For example, ‘‘B’’ in ‘‘NF-
kappa B’’ and ‘‘beta’’ in ‘‘NF kappa beta’’ are synon-
ymous. We introduce a new part-of-speech tag (@)
for a Roman and Greek alphabet.
s NF-kappa/NN B/NN
ﬁNF/NN -/- kappa/@ B/@
 Units frequently appear in scientiﬁc publication
including PubMed abstracts. They are sometimes
tagged as noun (NN) and sometimes tagged as adjec-
tive (JJ) in the part-of-speech annotated corpus. The
underlying rules for the part-of-speech ambiguity was
not obvious to us. We introduce a new part-of-speech
tag (UN) for units, to reduce annotation inconsis-
tency in the corpus.
s Examples of units are kDa, mg, . . .
 Tokens that were consecutively tagged as foreign
word (FW) in the original are merged into a single
token with the part-of-speech (FW). Our intention
is to reduce over-segmentation.
s in/FW vivo/FW
ﬁin vivo/FW5.3. Dictionary management
Since we treat biomedical English text as if it were
Japanese, we make no assumption about delimiting6 In the Penn Treebank tagging guideline, a string ‘‘to’’ is always
tagged as ‘‘TO,’’ irrespective of grammatical functionality. ‘‘TO’’ is an
example of a lexicalized tag.characters during construction of a trellis. Although seg-
mentation is possible at each character in Japanese, seg-
mentation in biomedical English is admissible only in
certain cases. We limit the potential tokenization ambi-
guity to occur around the cases below in addition to a
default space character:
 Symbols: delimit at / in ‘‘TCR/CD3 complex’’
 Numbers: delimit at 2 in ‘‘IL2’’
 Change of case: delimit at B in ‘‘NF-kappaB’’
The rest of trellis construction follows the same pro-
cedure as Japanese morphological analysis [23]. The dic-
tionary is organized in a TRIE structure. We apply
common preﬁx search to the dictionary where entries
can be compounds that include a space character (e.g.,
‘‘B-cell’’). The common preﬁx search eﬃciently retrieves
all substrings sharing the same preﬁx as the query string.
We use a Double Array as our implementation of the
TRIE [1].
By this mechanism, under-segmentation is reduced by
deﬁning admissible segmentation cases consisting of
more than just a space character. Moreover, the dictio-
nary allows entries which include a space character in
between since a space character is not a default delim-
iter. Thus, external resources containing multiple gra-
phic words can be imported into a dictionary, and
tokenization which avoids over-segmentation becomes
possible.
As a case study to enhance a dictionary of our mor-
phological analysis, we incorporate the latest GOA
gene_association.goa_human.gz (release of
November 11, 2003) [7] into the dictionary. GOA con-
tains associations between the vocabulary of GO and a
non-redundant set of proteins described in the SWISS-
PROT, TrEMBL, and Ensembl databases. This collec-
tively provides complete proteomes for Homo sapiens.
Since GENIA corpus 3.02 is indexed with MeSH terms
‘‘Human,’’ ‘‘Blood Cells,’’ and ‘‘Transcription Factor,’’
we ﬁnd this external resource appropriate for our pro-
tein name recognition. For a new entry from GOA not
observed in GENIA part-of-speech annotated corpus,
the part-of-speech is assigned to noun (NN), and the
word observation probability is set to the half of the
minimum word observation probability of noun (NN)
calculated from the annotated corpus. Hence, the prob-
ability of the new GOA entry is set to the half of the
minimum noun word observed in GENIA corpus.6. Experimental results
6.1. Data
GENIA corpus 3.02 contains 1998 abstracts once we
remove duplicated abstracts. We order abstracts by
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sorting, and split them into 10 sets. A general policy is
to train a model on an older set of abstracts and to test
it on a newer set of abstracts so as to simulate a situation
where protein name recognition is applied.
In our experiments, the latest 205 abstracts are used
for testing. Two sets of data are prepared for train-
ing—small and large. The small training data consists
of 594 abstracts from the beginning, while the large
training data consists of 1793 abstracts from the begin-
ning. The former is used to compare various results in
experimental settings, especially to examine the eﬀect
of tokenization to protein name recognition and robust-
ness to detecting unknown protein names. The latter is
intended for other research groups to compare our re-
sult with the standard data split using GENIA corpus
3.02.
6.2. Preprocessing
Table 2 summarizes various experimental settings.
First, we wish to estimate an upper bound of protein
name recognition using GENIA corpus 3.02. The ideal
1 uses annotated information from the merged corpus
with error-free tokenization and curated part-of-speech
annotation for biomedical NER. The ideal 2 uses anno-
tated information from the original part-of-speech
annotated. This may contain under-segmented tokeniza-
tion but curated part-of-speech annotation.
Next, we examine how much our augmented prepro-
cessing can be comparable to an ‘‘ideal’’ preprocessing.
The 594 abstracts of the modiﬁed GENIA described inTable 2
Experimental settings for various preprocessing
Training corpus Externals
ideal 1 n/a n/a
ideal 2 n/a n/a
proposed 1 Modiﬁed GENIA None
proposed 2 Modiﬁed GENIA GOA
conventional 1 PTB None
conventional 2 GENIA None
‘‘Training corpus’’ means a part-of-speech annotated corpus used in training
the Penn Treebank, and ‘‘GOA’’ stands for Gene Ontology Association. ‘‘To
and ‘‘part-of-speech tagging’’ is the method of part-of-speech taggers in tes
formation-based error-driven learning.
Table 3
List of characteristic tokens for semantic tag
Semantic tag Characteristic tokens
G#_protein Protein, factor, transcription, kinase, cytokine, complex, f
G#_DNA DNA, site, gene, enhancer, region, binding, element, repea
G#_cell Cell, lymphocyte, line, monocyte
G#_other Phosphorylation, activation, transduction, activity, produc
accumulation, concentrationSection 5.2 was used to train our morphological ana-
lyzer. The proposed 1 refers to a closed setting and the
proposed 2 refers to an open setting. In the open setting,
the external resource GOA is added to the dictionary.
Finally, we evaluate how our augmented preprocess-
ing performs against conventional preprocessing. As for
conventional preprocessing, we use the Penn Treebank
tokenizer and a part-of-speech tagger trained by the
fnTBL package [6] (transformation-based error-driven
learning, but a faster implementation of Brill Tagger),
since they are typically used in other publications (e.g.,
[5,20]). The conventional 1 uses Sections 15–19 of the
Penn Treebank Wall Street Journal for training, while
the conventional 2 uses the 594 abstracts of the original
GENIA part-of-speech annotated corpus.
6.3. Feature extraction
Since our purpose is to examine the eﬃcacy of pre-
processing, we keep features that can only be extracted
from the result of preprocessing:
 Part-of-speech annotation (POS)
 Cue word (CUE). This is also refereed to as ‘‘f-terms’’
in [5]. We count co-occurrence frequency of semantic
tag (G#) and all tokens in the corpus, and apply a
standard statistical hypothesis test to select tokens
that co-occur more frequently than by chance. Table
3 shows a subset of characteristic tokens for semantic
tag. For each characteristic token in Table 3, we
record its associated semantic tags to the comment
ﬁeld of a dictionary of our morphological analyzer.Tokenization Part-of-speech tagging
Curated Curated
Graphic word Curated
MM morphological analyzer
MM morphological analyzer
PTB tokenizer TBL
PTB tokenizer TBL
, and ‘‘externals’’ means if we use external resources. ‘‘PTB’’ stands for
kenization’’ is how we segment raw(unannotated) sentences in testing,
ting. ‘‘MM’’ stands for Markov model, and ‘‘TBL’’ stands for trans-
amily, subunit, antigen, antibody, mutant, ligand, receptor
t, motif, terminal, receptor, upstream, downstream, receptor, domain
tion, expression, proliferation, pathway, diﬀerentiation,
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in the dictionary contains its associated semantic tags
such as ‘‘G#_protein.’’ This feature is activated if
there is a semantic tag listed in the comment ﬁeld.
 External resource (GOA). For each new entry
imported from GOA, we record ‘‘GOA_HUMAN’’
to the comment ﬁeld of a dictionary of our morpho-
logical analyzer. This feature is activated if there is a
‘‘GOA_HUMAN’’ listed in the comment ﬁeld.
The role of the comment ﬁeld is to associate non-lin-
guistic information with linguistic (part-of-speech)
annotation for each token segmented by a morphologi-
cal analyzer. Recall that the morphological analyzer seg-
ments a sentence into tokens, and annotates the most
basic form of linguistic feature POS for each segmented
token. By embedding non-linguistic features CUE and
GOA in the comment ﬁeld of the dictionary used in
the morphological analyzer, we can annotate linguistic
and non-linguistic information simultaneously. Features
can be extracted without additional preprocessing. Pre-
processing in proposed 1 and proposed 2 are done in this
way.
In contrast, conventional preprocessing needs pipe-
lined modules to obtain linguistic feature POS and
non-linguistic features CUE and GOA for each token.
Thus, we execute a tokenizer, followed by a part-of-
speech tagger, and apply a separate module to match
each token against cue words and GOA entries in con-
ventional 1 and conventional 2.
6.4. Training
To train the model of chunk labels in a supervised
way, we use a SVM-based chunker, YamCha [12], which
is an open source software. Parameters used in YamCha
are as follows. In all settings, the context window size is
set to 2, i.e., information is extracted from tokens posi-
tioned 2, 1, 0 (focal token), +1, +2, and are con-
verted to feature vectors. A chunking direction are set
to forward, which means that chunk labels are estimated
from the top of the sentence. A fuller description of
chunking with SVMs can be found in [10].
Elements in features vectors represent simple features
obtained in Section 6.3, preﬁxed with the position
(2, . . .,+2). Combination of features (conjunctiveTable 4
Results with a large dataset: 1793 abstracts for training and 205 abstracts fo
P R F
proposed 1
strict 67.246 70.458 68.815
left 72.405 75.864 74.094
right 72.375 75.832 74.063
either 77.534 81.238 79.343
(P for precision, R for recall and F for F-measure).features) are implicitly expanded by the polynomial
kernel.
6.5. Results
Results are evaluated on four criteria: strict, left,
right, and either. The strict counts correct if both sides
of protein name boundaries are correct and the either
counts correct if either side of protein name boundaries
is correct. The left/right counts correct if left/right side of
protein name boundary is correct. Relaxed criteria
(either, left, and right) are used to account for annota-
tion inconsistency of protein name boundaries in the
corpus. A typical example of annotation inconsistency
is that a token ‘‘protein’’ in trailers is sometimes anno-
tated as a part of G#protein, and sometimes anno-
tated as outside G#protein. We view that the true
performance of protein name recognition lie between
strict and either criteria. To quantify the performance,
we use standard measures of precision, recall and F-
measure (Fb = 1).
Table 4 shows results with the large training dataset.
Our protein name recognition achieves an F-measure of
69.01 on strict criterion. F-measure goes up about 5
points when relaxing criteria to left or right side, and
about 10 points when relaxing criterion to either side.
The result on either criterion (F-measure of 79.32) sug-
gests that the protein name recognition could be used
to support biomolecular database curation involving
PubMed abstracts. We stress that a reasonable perfor-
mance is attained just by augmenting preprocessing,
and without resorting to ad hoc feature engineering.
Table 5 shows results with the small training dataset.
Our augmented preprocessing (proposed 1 and proposed
2) give better results than conventional preprocessing
(conventional 1 and conventional 2), by 1 point improve-
ment on strict criterion and 3.5 point improvement on
either criterion. On strict criterion, our augmented pre-
processing gives nearly the same performance as ideal
2 where only part-of-speech is curated by annotators.
On either criterion, our augmented preprocessing gives
nearly the same performance as ideal 1 where both tok-
enization and part-of-speech are curated by annotators.
Recall that ideal 1 is an estimated upper bound of pro-
tein name recognition with GENIA corpus 3.02. Thus,
eﬀectiveness in the use of morphological analysis, whichr testing
P R F
proposed 2
strict 67.517 70.678 69.061
left 72.740 76.147 74.405
right 72.320 75.707 73.975
either 77.544 81.175 79.318
Table 5
Results with a small dataset: 594 abstracts for training and 205 abstracts for testing
P R F P R F
ideal 1 ideal 2
strict 67.145 54.336 60.066 strict 68.818 51.602 58.979
left 72.776 58.893 65.103 left 73.637 55.216 63.110
right 71.650 57.982 64.095 right 72.841 54.619 62.428
either 77.281 62.539 69.133 either 77.661 58.233 66.558
proposed 1 proposed 2
strict 63.436 54.305 58.516 strict 62.757 54.651 58.424
left 69.236 59.270 63.867 left 68.819 59.930 64.068
right 68.685 58.799 63.359 right 68.098 59.302 63.396
either 74.486 63.764 68.709 either 74.160 64.582 69.040
conventional 1 conventional 2
strict 68.918 48.082 56.645 strict 67.768 49.622 57.293
left 74.549 52.011 61.273 left 72.961 53.425 61.683
right 73.738 51.445 60.607 right 72.274 52.922 61.103
either 79.369 55.373 65.235 either 77.467 56.725 65.493
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clature, is experimentally conﬁrmed.
There are other interesting observations in Table 5.
First, we compare results between ideal 1 and ideal 2
where the diﬀerence is whether a boundary disagreement
was curated by a human or not. (NB. The amount of
boundary disagreement is summarized in Table 1.) The
result indicates that tokenization ambiguity inﬂuences
the performance of protein name recognition. Turning
to proposed 1 and proposed 2 in Tables 4 and 5, the per-
formance improves when a large dataset is allowed for
training. However, only a small diﬀerence is observed
when a dictionary of morphological analysis is enhanced
with GOA entries. We still need to investigate eﬀective
exploitation of external resources. Finally, we compare
results between conventional 1 and conventional 2 where
the diﬀerence is the training corpus—‘‘in-domain’’
(GENIA) or ‘‘out-of-domain’’ (Penn Treebank). Perfor-
mance is slightly improved when preprocessing is
trained on ‘‘in-domain’’ part-of-speech annotated cor-
pus, which agrees with the previous work.
6.6. Discussion
We examine how these learned models are robust
against ‘‘unknown’’ protein names. By unknown, we
mean that the protein names are only found in the train-
ing data of 594 abstracts. There are 1876 instances in the
test data. Table 6 shows the results of unknown proteinTable 6
Performance of ‘‘unknown’’ protein name recognition
P R F
ideal 1 54.926 41.311 47.155
proposed 1 50.711 39.925 44.676
conventional 1 56.594 36.141 44.112name recognition on strict criterion. Except ideal cases,
proposed 2 of the open setting achieves the best recall
(40.35), and conventional 1 trained on Penn Treebank
achieves the best precision (56.59). Under a simulated
situation of changing nomenclature, we observe a trend
that our augmented preprocessing gives better recall
while conventional preprocessing gives better precision.
Our morphological analyzer attempts to avoid under-
segmentation and produces ﬁne-grained tokens. This
implies that the dimension of the feature space from
our augmented preprocessing becomes lower than the
dimension of feature space from conventional prepro-
cessing. The dimensions of feature space for proposed
2 and conventional 2 are 20,076 and 24,961, respectively.
The model of proposed 2 tends to be more generalized,
and a better recall is obtained. On the other hand, a low-
er precision is due to the ﬁne-grained tokenization in
that narrower neighboring substrings are converted to
feature vectors than in conventional preprocessing. We
still need to investigate a good balance between preci-
sion and recall for unknown protein name recognition.
Finally, we compare execution speed of preprocess-
ing. Sixteen thousand four hundred and sixty seven sen-
tences from 1998 abstracts were processed on a
2.20 GHz processor with 1 GB memory. Table 7 shows
the cpu time taken. Our morphological analyzer is sub-
stantially faster than conventional preprocessing. The
gain in speed is important when we need to process volu-
minous texts such as PubMed abstracts.P R F
ideal 2 57.023 39.819 46.893
proposed 2 49.737 40.352 44.556
conventional 2 55.111 36.780 44.118
Table 7
Execution speed of preprocessing in seconds: (a) tokenization, (b) part-
of-speech tagging
(a) (b) Total
proposed 7.19 7.19
conventional 7.87 67.22 75.07
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We propose the use of morphological analysis in
protein name recognition. Our contributions are (1) to
illustrate problems stemming from conventional prepro-
cessing, in particular boundary disagreement which has
been overlooked in biomedical text processing, and (2)
to propose morphological analysis as a way to overcome
the problems.We obtainF-measure performance of 69.01
on a strict criterion and 79.32 on a relaxed criterion with
GENIA corpus 3.02. We show that our augmented pre-
processing improves the performance of protein name
recognition over conventional preprocessing.
A major limitation of our work is that our protein
name recognition requires a labor-intensive annotated
corpus, as it is a supervised learning approach. To in-
crease both accuracy and coverage, we will need to
investigate ways to apply a semi- or un-supervised ap-
proach that eﬀectively uses ample unlabeled data, as
proposed in [4]. Another criticism with supervised learn-
ing approaches, especially SVMs, is scalability. SVMs
show excellent performance in terms of accuracy, but
are generally slow to execute. Recently, authors in [11]
have proposed an approximation method for text anal-
ysis with the polynomial kernel, which makes trained
classiﬁers substantially faster while keeping the same le-
vel of accuracy. Such research development is on-going
in NLP (and Bioinformatics), we envision that the issue
of scalability will not be critical in near future.
As future work, a possible direction is linking a pro-
tein name to a protein sequence. Our protein name rec-
ognition detects protein names in an abstract. A next
step to assist database curators will be to suggest candi-
dates of corresponding protein sequences. A similar line
of motivation is found in Task 1.B of BioCreAtIve Eval-
uation where the task is to create the list of unique genes
that are mentioned in an abstract referenced by a model
organism database. Our morphological analyzer par-
tially facilitates cross-linking by inserting accession
IDs in a comment ﬁeld of the relevant entry in the dic-
tionary. It would be interesting to investigate ways to
achieve accurate assignment of sequence IDs.Acknowledgments
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